Mafalda Oliveira
Overview
Explore the profile of Mafalda Oliveira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
3817
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papakonstantinou A, Villacampa G, Navarro V, Oliveira M, Valachis A, Pascual T, et al.
EClinicalMedicine
. 2025 Mar;
81:103116.
PMID: 40034565
Background: Multiple trials have evaluated escalation strategies of endocrine therapy for early breast cancer, including ovarian function suppression (OFS) and aromatase inhibitors (AI) in premenopausal patients and extended endocrine therapy....
2.
Pathak N, Oliveira M
Annu Rev Med
. 2025 Jan;
76(1):243-255.
PMID: 39869433
Oral selective estrogen receptor degraders (SERDs) are pure estrogen receptor antagonists that have the potential to overcome common resistance mechanisms to endocrine therapy in estrogen receptor-positive breast cancer. There are...
3.
Ribeiro M, Oliveira M, Nogueira V, Costa V, Teixeira V
Cell Commun Signal
. 2025 Jan;
23(1):10.
PMID: 39773523
Background: Seipin is a protein encoded by the BSCL2 gene in humans and SEI1 gene in yeast, forming an Endoplasmic Reticulum (ER)-bound homo-oligomer. This oligomer is crucial in targeting ER-lipid...
4.
Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, et al.
Lancet Oncol
. 2024 Oct;
25(11):1424-1439.
PMID: 39481395
Background: Resistance to endocrine therapies in hormone receptor-positive breast cancer is challenging. We aimed to assess the next-generation oral selective oestrogen receptor degrader (SERD) and complete oestrogen receptor antagonist, camizestrant,...
5.
Turner N, Oliveira M, Howell S, Dalenc F, Cortes J, Gomez H, et al.
Future Oncol
. 2024 Sep;
20(37):2901-2913.
PMID: 39283299
What Is This Summary About?: This is a summary of the article discussing the results of the CAPItello-291 study. In the study, participants had advanced breast cancer that could not...
6.
Jhaveri K, Accordino M, Bedard P, Cervantes A, Gambardella V, Hamilton E, et al.
J Clin Oncol
. 2024 Sep;
42(33):3947-3956.
PMID: 39236276
Purpose: To investigate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of inavolisib, a potent and selective small-molecule inhibitor of p110α that promotes the degradation of mutated p110α, in...
7.
Oliveira M, Rugo H, Howell S, Dalenc F, Cortes J, Gomez H, et al.
Lancet Oncol
. 2024 Aug;
25(9):1231-1244.
PMID: 39214106
Background: CAPItello-291 is an ongoing phase 3 trial in which capivasertib-fulvestrant significantly improved progression-free survival versus placebo-fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer who had relapse or...
8.
Villacampa G, Navarro V, Matikas A, Ribeiro J, Schettini F, Tolosa P, et al.
JAMA Oncol
. 2024 Aug;
10(10):1331-1341.
PMID: 39207778
Importance: Recent studies have investigated the combination of immune checkpoint inhibitors (ICIs) with (neo)adjuvant chemotherapy in early-stage breast cancer. However, there is an ongoing debate about the optimal approach for...
9.
Dent R, Kim S, Oliveira M, Barrios C, OShaughnessy J, Isakoff S, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4329-4338.
PMID: 39058425
Purpose: In the randomized phase II LOTUS trial, combining ipatasertib with first-line paclitaxel for triple-negative breast cancer (TNBC) improved progression-free survival (PFS), particularly in patients with PIK3CA/AKT1/PTEN-altered tumors. We aimed...
10.
Sanchez-Bayona R, Oliveira M
Ann Oncol
. 2024 Jul;
35(8):689-691.
PMID: 39048261
No abstract available.